HRP20120073T1 - NOVI KRISTALNI OBLIK DERIVATA PIRIDAZINO[ b]INDOLA - Google Patents

NOVI KRISTALNI OBLIK DERIVATA PIRIDAZINO[ b]INDOLA Download PDF

Info

Publication number
HRP20120073T1
HRP20120073T1 HRP20120073TT HRP20120073T HRP20120073T1 HR P20120073 T1 HRP20120073 T1 HR P20120073T1 HR P20120073T T HRP20120073T T HR P20120073TT HR P20120073 T HRP20120073 T HR P20120073T HR P20120073 T1 HRP20120073 T1 HR P20120073T1
Authority
HR
Croatia
Prior art keywords
prevention
treatment
intended
crystalline form
pharmaceutical preparation
Prior art date
Application number
HRP20120073TT
Other languages
English (en)
Croatian (hr)
Inventor
William@L@@Rocco
John@D@@Higgins
Original Assignee
Sanofi@Aventis@U@S@@LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37546937&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20120073(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi@Aventis@U@S@@LLC filed Critical Sanofi@Aventis@U@S@@LLC
Publication of HRP20120073T1 publication Critical patent/HRP20120073T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HRP20120073TT 2005-08-29 2006-08-24 NOVI KRISTALNI OBLIK DERIVATA PIRIDAZINO[ b]INDOLA HRP20120073T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71215305P 2005-08-29 2005-08-29
PCT/US2006/033254 WO2007027525A1 (fr) 2005-08-29 2006-08-24 Nouvelle forme cristalline d'un derive de pyridazino [4,5-b]indole

Publications (1)

Publication Number Publication Date
HRP20120073T1 true HRP20120073T1 (hr) 2012-07-31

Family

ID=37546937

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20120073TT HRP20120073T1 (hr) 2005-08-29 2006-08-24 NOVI KRISTALNI OBLIK DERIVATA PIRIDAZINO[ b]INDOLA

Country Status (31)

Country Link
US (1) US7683062B2 (fr)
EP (1) EP1924585B1 (fr)
JP (1) JP5063600B2 (fr)
KR (2) KR20080050577A (fr)
CN (1) CN101253176B (fr)
AR (1) AR057099A1 (fr)
AT (1) ATE531717T1 (fr)
AU (1) AU2006285142B2 (fr)
BR (1) BRPI0615259A2 (fr)
CA (1) CA2619284C (fr)
CR (1) CR9723A (fr)
CY (1) CY1112317T1 (fr)
DK (1) DK1924585T3 (fr)
EA (1) EA014164B1 (fr)
EC (1) ECSP088209A (fr)
ES (1) ES2375841T3 (fr)
HR (1) HRP20120073T1 (fr)
IL (1) IL189276A (fr)
MA (1) MA30000B1 (fr)
NO (1) NO20081365L (fr)
NZ (1) NZ566087A (fr)
PL (1) PL1924585T3 (fr)
PT (1) PT1924585E (fr)
RS (1) RS52318B (fr)
SI (1) SI1924585T1 (fr)
TN (1) TNSN08059A1 (fr)
TW (1) TW200813060A (fr)
UA (1) UA91716C2 (fr)
UY (1) UY29771A1 (fr)
WO (1) WO2007027525A1 (fr)
ZA (1) ZA200801890B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2545968C (fr) * 2003-11-17 2010-03-09 Merck Eprova Ag Formes cristallines de dihydrochlorure de (6r)-l-erythro-tetrahydrobiopterine
US20070249827A1 (en) * 2004-06-02 2007-10-25 Sandoz Ag Meropenem Intermediatein in Crystalling Form
EA018698B1 (ru) * 2005-09-21 2013-10-30 4Сц Аг Сульфонилпирролгидрохлориды как ингибиторы гистондезацетилазы
EP2404911A1 (fr) * 2005-10-31 2012-01-11 Janssen Pharmaceutica NV Nouveaux procédés pour la préparation de dérivés de pipérazinyle et diazépanyle benzamide
MX2008016008A (es) * 2006-06-16 2009-01-16 Lundbeck & Co As H Formas cristalinas de 4-[2-(4-metilfenilsulfonil)-fenil] piperidina con inhibicion combinada de la recaptacion de serotonina y norepinefrina para el tratamiento del dolor neuropatico.
NZ576347A (en) * 2006-10-27 2011-10-28 Signal Pharm Llc Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and use therewith
EP2085397A1 (fr) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Forme cristalline d'abacavir
US7935817B2 (en) * 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
AR071318A1 (es) * 2008-04-15 2010-06-09 Basilea Pharmaceutica Ag Benzhidril ester del acido (6r,7r)-7-{2-(5-amino-[1,2,4]tiadiazol-3-il)-2-[(z)-tritiloxiimino]-acetilamino}-3-[(r)-1'-terc-butoxicarbonil-2-oxo-[1,3']bipirrolidinil-(3e)-ilidenometil]-8-oxo-5-tia-1-aza-biciclo[4.2.0]oct-2-eno-2-carboxilico cristalino; su elaboracion y uso
US8097719B2 (en) * 2008-07-15 2012-01-17 Genesen Labs Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem
AU2009283039A1 (en) * 2008-08-18 2010-02-25 Sanofi-Aventis U.S. Llc Process for preparing polymorph of 7-chloro-N, N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydr0-4H-pyridazin0[4,5-b]indole-1-acetamide
NZ601967A (en) 2010-03-12 2015-03-27 Omeros Corp Pde10 inhibitors and related compositions and methods
KR20130101524A (ko) * 2010-09-01 2013-09-13 아레나 파마슈티칼스, 인크. 5-ｈｔ2ｃ 아고니스트의 비-흡습성 염
WO2013044816A1 (fr) * 2011-09-30 2013-04-04 Sunshine Lake Pharma Co., Ltd. Formes cristalline d'azilsartan et leur préparation et leurs utilisations
NZ716462A (en) * 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
NZ630810A (en) 2014-04-28 2016-03-31 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
CA2980801A1 (fr) 2015-04-24 2016-10-27 Omeros Corporation Inhibiteurs de pde10 ainsi que compositions et procedes associes
CA3003611C (fr) 2015-11-04 2022-11-01 Omeros Corporation Formes solides d'un inhibiteur de pde10
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN111303230B (zh) * 2020-03-09 2021-07-13 中国食品药品检定研究院 一种黄体酮共晶物及其制备方法和用途
WO2026130526A1 (fr) * 2024-12-20 2026-06-25 杭州百新生物医药科技有限公司 Composé tricyclique et utilisation médicale de celui-ci

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2766823B1 (fr) * 1997-07-30 1999-10-08 Synthelabo Derives de 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b] indole-1-acetamide, leur preparation et leur application en therapeutique
FR2788696B1 (fr) * 1999-01-26 2004-03-05 Synthelabo Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central
FR2829939B3 (fr) 2001-09-21 2003-11-28 Sanofi Synthelabo Utilisation du 7-chloro-n,n,5-trimethyl-4-oxo-3-phenyl-3,5- dihydro-4h-pyridazino(4,5-b)indole-1-acetamide pour la preparation de medicaments destines au traitement de la polyarthrite rhumatoide
US20050220881A1 (en) 2003-10-10 2005-10-06 Bvm Holding Co. Pharmaceutical composition

Also Published As

Publication number Publication date
KR20130087059A (ko) 2013-08-05
TNSN08059A1 (en) 2009-07-14
US7683062B2 (en) 2010-03-23
US20080139569A1 (en) 2008-06-12
KR20080050577A (ko) 2008-06-09
EP1924585A1 (fr) 2008-05-28
JP5063600B2 (ja) 2012-10-31
MA30000B1 (fr) 2008-12-01
AR057099A1 (es) 2007-11-14
ECSP088209A (es) 2008-06-30
WO2007027525A1 (fr) 2007-03-08
UY29771A1 (es) 2007-03-30
NZ566087A (en) 2011-03-31
PL1924585T3 (pl) 2012-08-31
PT1924585E (pt) 2012-01-19
AU2006285142A1 (en) 2007-03-08
CA2619284A1 (fr) 2007-03-08
CY1112317T1 (el) 2015-12-09
CN101253176B (zh) 2012-04-18
CN101253176A (zh) 2008-08-27
JP2009506116A (ja) 2009-02-12
RS52318B (sr) 2012-12-31
IL189276A (en) 2012-07-31
UA91716C2 (ru) 2010-08-25
NO20081365L (no) 2008-04-03
HK1123794A1 (en) 2009-06-26
TW200813060A (en) 2008-03-16
DK1924585T3 (da) 2012-02-27
BRPI0615259A2 (pt) 2011-05-17
EA014164B1 (ru) 2010-10-29
CR9723A (es) 2008-06-18
IL189276A0 (en) 2008-08-07
ZA200801890B (en) 2009-11-25
AU2006285142B2 (en) 2012-06-14
ATE531717T1 (de) 2011-11-15
SI1924585T1 (sl) 2012-09-28
ES2375841T3 (es) 2012-03-06
EA200800716A1 (ru) 2008-08-29
EP1924585B1 (fr) 2011-11-02
CA2619284C (fr) 2014-04-29

Similar Documents

Publication Publication Date Title
US10017513B2 (en) Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido [5,4-D][2]benzazepin-2-YL]amino}-2-methoxybenzoate
CN117247382A (zh) 吡啶并嘧啶酮化合物的晶型
CA2980888C (fr) Cristal d'un compose d'alcynyle de benzene 3,5-disubstitue
CN114437077B (zh) 用作激酶抑制剂的化合物及其应用
JPH08337584A (ja) 縮合六環式アミノ化合物、これを含有する医薬及びその製法
CN104817559B (zh) 氘代喹唑啉酮化合物以及包含该化合物的药物组合物
EP3988546A1 (fr) Sels de composés, leurs formes cristallines, procédé de préparation correspondant et utilisation associée
CN114667288A (zh) 苯并菲啶生物碱及其使用方法
CN103396470B (zh) Withanolides型化合物及其抗肿瘤的用途
CN114456140B (zh) 一种淫羊藿苷元与茶碱的共晶
WO2016098070A1 (fr) Forme cristalline de la 5-chloro-n2-(2-isopropoxy-5-méthyl-4-pipéridin-4-yl-phényl)-n4-[2-(propane-2-sulfonyl)-phényl]-pyrimidine-2,4-diamine
CN117355528B (zh) 吡咯并三嗪类化合物的盐型、其晶型及其制备方法
CN115038702B (zh) 一种芳胺基嘌呤衍生物的盐及其制备方法和应用
EP4740944A2 (fr) Formes solides de 3-(5-fluorobenzofuran-3-yl)-4-(5-méthyl-5h-[1,3!dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
US20240391902A1 (en) Crystalline Form of Compound
CN108440572B (zh) 一种青蒿琥酯衍生物及其制备方法及应用
CN112830930B (zh) Eoc317的晶型及其制备方法与应用
AU2005318227B2 (en) Stereoselective process and crystalline forms of a camptothecin
EP3345898B1 (fr) Cristaux d'acide 5-cyclopropyl-2-((1-(3-fluorobenzyl)-1h-indol-5-yl)amino)nicotinique
JP5701884B2 (ja) 三環性ピラゾロピリミジン誘導体の結晶
CN109251218A (zh) 一种取代的硼酸酯化合物的制备方法及其晶型
CN107840852A (zh) 氘代阿格拉滨二甲胺富马酸盐，制备方法及其在药物制备中的用途
WO2023197934A1 (fr) Forme de sel solide d'un conjugué antagoniste du récepteur opioïde, forme cristalline, procédé de préparation associé, composition et utilisation
CN116529249A (zh) 吡啶并嘧啶酮类化合物
HK40072576A (en) Compound used as kinase inhibitor and use thereof